A neurotechnology company has launched a multisite study to assess its technology in the continuous monitoring of patients with movement disorders, such as those associated with Parkinson’s disease.
Great Lakes NeuroTechnologies‘ will follow 60 patients with essential tremor, a type of involuntary shaking of the body, as they conduct their daily lives in their homes, according to a statement from the Cleveland-based company.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Great Lakes’ Kinesia movement disorder assessment technology uses a ring-like sensor worn on a patient’s finger to measure motor symptoms and wirelessly transmit data on the severity of a patient’s tremors.
Understanding the type and severity of tremors a patient experiences will help doctors better prescribe medications to minimize the patient’s fluctuations throughout the course of a day, according to Great Lakes.
“Expanding our portfolio to essential tremor can increase technology adoption in the movement disorders market,” said CEO Joe Giuffrida. “Clinically validating the system for continuous monitoring of symptom severity during any daily activity also opens new markets for pharmaceutical trials.”
The study is funded via a grant from the National Institutes of Health.
Great Lakes is planning several clinical studies this year, including one evaluating its technology for use in conjunction with deep brain stimulation treatment of Parkinson’s patients.
